Schubert & Co’s Amneal Pharmaceuticals AMRX Stock Holding History

Schubert & Co’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-21	Closed	–	–	1366
2022 Q2	$0	Buy	21 +20	+2,000%	+$72	﹤0.01%	1428
2022 Q1	$0	Buy	+1	New	+$4	﹤0.01%	1062

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schubert & Co's AMRX Position: Q3 2022 in Review

Schubert & Co sold out of Amneal Pharmaceuticals (AMRX) in Q3 2022, closing a stake of 21 shares.

Schubert & Co first reported a position in AMRX in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 154 funds tracked by Wall St. Rank hold AMRX as of Q3 2022.

Schubert & Co reported no remaining Amneal Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Schubert & Co sold 21 Amneal Pharmaceuticals shares in Q3 2022.
Schubert & Co first reported a position in Amneal Pharmaceuticals in Q1 2022 and held it in 2 quarters.
Schubert & Co's Amneal Pharmaceuticals position peaked at $0 in Q2 2022.
154 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2022.

Based on Schubert & Co's 13F filing for Q3 2022, filed 21 Oct 2022.